Cognitive

Peptides used as nootropics or studied for neuroprotection. Several have regional clinical history but limited independent RCT evidence.

Community-reported ranges are anecdotal and not clinically validated. Evidence grade shown reflects the strength of available human data. Not a prescription. Legal status varies by country and changes over time; verify locally.

5 peptides

Semax

Human observational

A peptide developed in Russia and used there in some clinical settings; used elsewhere as a nootropic. Evidence outside its origin is limited.

Selank

Human observational

An anxiolytic peptide developed in Russia. Like Semax, it has regional clinical history but limited independent evidence.

Dihexa

Animal / preclinical

N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, PNB-0408

A small angiotensin IV–derived peptide developed in preclinical Alzheimer's research for its potent synapse-forming effects. There is no human trial evidence, and its mechanism raises unanswered safety questions.

Cerebrolysin

Human RCT

FPF-1070

A mixture of low-molecular-weight peptides and amino acids derived from pig brain, approved in a number of countries for stroke, dementia and traumatic brain injury. It is not approved in the US or UK, and trial results are mixed.

Pinealon

Anecdote / community

Glu-Asp-Arg, EDR peptide

A short 'peptide bioregulator' (tripeptide) promoted for brain function, largely based on the work of a single research group. Independent human evidence is very limited.